Sounding the alarm on deaths from suicide and accidents after hematopoietic stem cell transplantation
F. Loberiza,A. Cannon
DOI: https://doi.org/10.1002/cncr.27982
IF: 6.9209
2013-06-01
Cancer
Abstract:High-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT)is an accepted mode of treatment for a variety of malignant and nonmalignant disorders. Although its outcomes have dramatically improved over the years largely due to advances in donor–recipient human leukocyte antigen–matching and aggressive prevention or treatment of complications, disease relapse or progression and transplant-related complications remain the most common causes of deaths among patients who undergo HSCT. However, among survivors who underwent HSCT, a longitudinal cohort study by Syrjala and colleagues found that a significant number continue to have deficits in physical and mental well-being even after 5 years. Survivors continue to significantly have treatment-related distress. Deficits in both physical (pain and loss of mobility) and mental well-being (depression, anxiety, distress) have been shown to be significant risk factors for suicide and accidental deaths. In addition, having chronic medical conditions, such as cancer, is also a risk factor for suicide and accidental death. In this issue of Cancer, Tichelli and colleagues elegantly examined retrospectively a large database from the European Group for Blood and Marrow Transplantation (EBMT) to determine the incidence rates and transplant-related risk factors associated with deaths from external causes, that is, suicides or accidents after HSCT. They also evaluated if the rates of suicide or accidental deaths after HSCT are significantly higher compared with the general European population. The study included 294,922 patients who underwent autologous or allogeneic HSCT from 1980 to 2009 for various malignant and nonmalignant disorders. The cohort represented 661 transplant centers from 53 countries in Europe. Causes of death were reported by transplant centers to the EBMT central repository, using a variety of sources. The study found that suicide rates after HSCT was higher at 20.7 per 100,000 person-years (PY) compared with 9.2 per 100,000 PY for the general European population. This represents an odds ratio of 2.12, or elevated risk of death from suicide. Similarly, accidental deaths after HSCT was higher at 13.7 per 100,000 PY compared with 10.5 per 100,000 PY for the general European population. This represents an odds ratio of 1.23, or elevated risk of death from accidents. Although the majority of the deaths from suicide after HSCT occurred within the first year (at 46%), 15% occurred during the second year, and rates as high as 17% occurred even after 5 years. On the other hand, 30% of accidental deaths after HSCT occurred within the first year, 18% during the second year, and rates as high as 24% occurred even after 5 years. Although the age range of patients who died from suicide is wide, the mean age was 45 years, with 74% of patients being males. Most suicides were in patients who received autologous HSCT (61%) versus 39% in patients who received allogeneic HSCT. The mean age of patients who died from accidents was 41, also predominantly occurring in males (74%) and among recipients of autologous HSCT (62%). Traffic accident was the predominant cause of accidental deaths. The authors also conducted a separate nested case-control analysis matching each HSCT patient who died from suicide or accidents with 3 patients according to type of HSCT, age, sex, year of transplant, and length of follow-up. In the setting of autologous HSCT, the presence of relapse was associated with increased likelihood of death from either suicide or accident, with odds ratio of 4.48 and 2.36, respectively. In the setting of allogeneic HSCT, development of chronic graft-versus-host disease was associated with increased likelihood of death from suicide, with odds ratio of 2.91. No factors were found to be associated with risk of death from accidents in allogeneic HSCT. Type of disease and disease stage (early versus advanced stage) were not associated with likelihood of death from suicide or accidents.